CreatorsPublishersAdvertisers
View more in
Markets

Centessa Stock Surges On Positive Data From Hemophilia Candidate

Benzinga
Benzinga
 2021-09-09
Cover picture for the article

Centessa Pharmaceuticals plc (NASDAQ: CNTA) has announced positive topline results from the Phase 2a part of AP-0101, the six-month repeat dose portion of the study evaluating SerpinPC in severe hemophilia A and B patients. SerpinPC was well-tolerated. As previously disclosed, one subject with a...

www.benzinga.com

Comments / 0

Comments / 0